Medication adherence and clinical outcomes in patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, British Medical Journal Open Respiratory Research, April 5, 2025

The findings of a prospective study on 93 patients (66% women, 75% PAH, 25% CTEPH, 57±17 years), all on pulmonary hypertension-targeted oral medication, between 2013 and 2023, were recently published in the British Medical Journal Open Respiratory Research. These reveal that mean MPR (Medication Possession Ratio) and self-reported adherence were overall high, with 78% of patients […]

Medication adherence and clinical outcomes in patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, British Medical Journal Open Respiratory Research, April 5, 2025 Read Post »

Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox, International Journal of Cardiology Congenital Heart Disease, March 2025

Pulmonary arterial hypertension (PAH), once seen mostly in young, healthy women, is now common among older adults with comorbidities in North America and Europe. In contrast, Latin American patients remain younger and healthier, with fewer related conditions. Possible Reasons Current Situation Latin American pulmonary arterial hypertension patients have: Future Concerns Rising obesity and aging populations

Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox, International Journal of Cardiology Congenital Heart Disease, March 2025 Read Post »

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death, New England Journal of Medicine, March 31, 2025

An article published in the New England Journal of Medicine on March 31 titled “Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death” reports on the findings of ZENITH, a phase 3 trial which evaluated sotatercept as an add-on therapy for high-risk pulmonary arterial hypertension patients (functional class II-IV) already on maximum

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death, New England Journal of Medicine, March 31, 2025 Read Post »

Breaking news! Important update on the ZENITH trial on Winrevair (sotatercept) in pulmonary arterial hypertension from the American College of Cardiologists Scientific Annual Scientific Session, March 31, 2025

A very important update on the phase 3 ZENITH trial for Winrevair (sotatercept) in pulmonary arterial hypertension was presented today at the American College of Cardiologists Annual Scientific Session in Boston, USA. The ZENITH trial evaluated Winrevair compared to placebo in adults with PAH, WHO Group 1, functional class III or IV, at high risk

Breaking news! Important update on the ZENITH trial on Winrevair (sotatercept) in pulmonary arterial hypertension from the American College of Cardiologists Scientific Annual Scientific Session, March 31, 2025 Read Post »

Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose Finding Phase 2 Study, American Journal for Respiratory Critical Care Medicine, March 2025

Imatinib for pulmonary arterial hypertension was the first antiproliferative approach in this condition’s treatment and may still be relevant today despite its complicated history. Originally developed as a cancer therapy (tyrosine kinase inhibitor), it showed very good results in pulmonary arterial hypertension, creating a lot of expectation when the IMPRES study was presented at the

Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose Finding Phase 2 Study, American Journal for Respiratory Critical Care Medicine, March 2025 Read Post »

Should sex differences be taken into account when conducting a risk assessment for pulmonary arterial hypertension patients? International Journal of Cardiology, March 20, 2025

In a multicenter study from the FOCUS-PAH registry (2001-2022), researchers examined sex differences among 410 pulmonary arterial hypertension patients, and found that women represented 2 out of 3 patients (66.6 %) vs 33.4%). The findings, published in the International Journal of Cardiology on March 20, 2025 in an article titled “Sex differences in pulmonary arterial

Should sex differences be taken into account when conducting a risk assessment for pulmonary arterial hypertension patients? International Journal of Cardiology, March 20, 2025 Read Post »

Miniature three dimensional arterial structures may allow proxy evaluation of human pulmonary artery contractility, British Journal of Pharmacology, February 20, 2025

The authors of a study titled “Engineered pulmonary artery tissues for measuring contractility, drug testing and disease modelling”, published in the British Journal of Pharmacology on Ferbruary 20, 2025, present an innovative technique to allow proxy evaluation of human pulmonary artery contractility. Vasoreactivity of the pulmonary arteries regulates blood flow through the lungs,they say, and

Miniature three dimensional arterial structures may allow proxy evaluation of human pulmonary artery contractility, British Journal of Pharmacology, February 20, 2025 Read Post »

Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients, The Lancet, February 20, 2025

An article titled “Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients”, was published in The Lancet on February 20, 2025. It reports on discussions held between a group of international experts at the 20th Global CardioVascular Clinical Trialists Forum, CVCT (Washington DC, USA), patients’ representatives, and members

Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients, The Lancet, February 20, 2025 Read Post »

Interview with Louise Bouman, Chair of the Dutch Pulmonary Hypertension Association on the importance of patient involvement in healthcare policies and drug development

Louise Bouman, Chair of the Dutch Pulmonary Hypertension Association, was recently invited to share her experience as a EUPATI Nederland fellow. Pulmonary Hypertension: Rare and Complex In pulmonary hypertension, blood pressure in the lung vessels is too high due to narrowing of the pulmonary arteries. This overloads the right heart chamber, making it increasingly difficult

Interview with Louise Bouman, Chair of the Dutch Pulmonary Hypertension Association on the importance of patient involvement in healthcare policies and drug development Read Post »

New data on seralutinib presented at the Pulmonary Vascular Research Institute conference in Rio, January 29-February 1, 2025

Gossamer Bio, Inc. presented clinical and preclinical data related to its investigational drug seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress that took place January 29th through February 1st in Rio de Janeiro, Brazil. Of particular interest the data on sustained benefit of seralutinib over nearly 1.5 years, and the evidence, from preclinical

New data on seralutinib presented at the Pulmonary Vascular Research Institute conference in Rio, January 29-February 1, 2025 Read Post »

The US Food and Drug Administration (FDA) has approved clinical trials to transplant organs from genetically modified pigs into people with kidney failure

The US Food and Drug Administration (FDA) has approved pioneering clinical trials by two biotech firms to evaluate the transplantation of kidneys from genetically engineered pigs into human patients with renal failure. This breakthrough authorization could mark a significant step toward addressing the chronic shortage of human organs for transplant. Until now, such transplants were

The US Food and Drug Administration (FDA) has approved clinical trials to transplant organs from genetically modified pigs into people with kidney failure Read Post »

Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies, European Respiratory Journal, January 30, 2025

This post-hoc, exploratory pooled analysis, published on January 30, 2025, on the European Respiratory Journal, combines data from the Phase 2 PULSAR and Phase 3 STELLAR studies on sotatercept, both international, multicentre, randomised, double-blind, placebo-controlled trials in pulmonary arterial hypertension patients. Out of 429 randomised patients, 237 received sotatercept and 192 placebo. After 24 weeks,

Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies, European Respiratory Journal, January 30, 2025 Read Post »

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis

Merck/MSD announced today that the Phase 3 HYPERION trial on pulmonary arterial hypertension patients (Group 1 World Health Organisation) in functional class II-III was suspended. Patients in the study will be offered the option of receiving WINREVAIR through the Phase 3 SOTERIA open-label extension study. Findings from the HYPERION study will be available later this

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis Read Post »

The Dutch Pulmonary Hypertension Association has contributed financially to the RECOMPENSE Phase 4 study on sotatercept conducted by the Amsterdam University Medical Center

The Dutch Pulmonary Hypertension Association, Stichting Pulmonale Hypertensie, has contributed financially with an amount of € 40.000 the RECOMPENSE – Right VEntricular COMPENsation with SotatercEpt – Phase 4 study conducted by the Amsterdam UMC. This research aims to investigate sotatercept’s effects on right ventricular function. Background Several large international studies have already been conducted in

The Dutch Pulmonary Hypertension Association has contributed financially to the RECOMPENSE Phase 4 study on sotatercept conducted by the Amsterdam University Medical Center Read Post »

Prognostic relevance of exercise pulmonary hypertension: results of the multicentre PEX-NET Clinical Research Collaboration, European Respiratory Journal

The PEX-NET (Pulmonary Haemodynamics during Exercise Network) registry enrolled patients who underwent clinically indicated right heart catheterisations both at rest and ergometer exercise from 23 PH centres worldwide. The aim of the study was to explore the prognostic relevance of exercise haemodynamics and its added value to resting haemodynamics are missing. The study finds that

Prognostic relevance of exercise pulmonary hypertension: results of the multicentre PEX-NET Clinical Research Collaboration, European Respiratory Journal Read Post »

Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population, Nature Briefing Journal, January 15, 2025

The study published recently in the Nature Briefing Journal explores using mathematical modeling to address drug development challenges in pulmonary arterial hypertension. Researchers developed a quantitative systems pharmacology (QSP) model in the context of oral treprostinil clinical studies to predict changes in pulmonary vascular resistance and six-minute walk distance by creating a virtual patient population

Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population, Nature Briefing Journal, January 15, 2025 Read Post »

Positive scientific advice from the US Food and Drug Administration (FDA) for a Phase 2 clinical trial of tiprelestat in pulmonary arterial hypertension

Tiakis Biotech has received positive scientific advice from the US Food and Drug Administration (FDA) for a planned Phase 2 ATHENA clinical trial of tiprelestat in pulmonary arterial hypertension. The therapy has been granted orphan designation in the U.S. and in Europe for pulmonary arterial hypertension. Dr. Roham Zamanian, Professor of Medicine at Stanford University and

Positive scientific advice from the US Food and Drug Administration (FDA) for a Phase 2 clinical trial of tiprelestat in pulmonary arterial hypertension Read Post »

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants!

The Alliance for Pulmonary Hypertension (AfPH) recently concluded its 14th webinar, marking the culmination of an educational initiative that began in June 2023. These virtual gatherings brought together internationally renowned experts in pulmonary hypertension, who shared their expertise on a comprehensive range of topics crucial to advancing patient care and quality of life. The diverse

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants! Read Post »

Bridging the Gender Gap: Addressing Women’s Underrepresentation in Cardiovascular Research, American Journal of Managed Care, October 15, 2024

According to an article titled ‘Why are we still seeing gaps in women’s heart care’ by Hayden E. Klein, published on ‘The American Journal of Managed Care’ on October 15, 2024, women remain underrepresented in heart disease trials, thus affecting the generalizability of findings due to sex-based differences.  For years, women were underrepresented in cardiovascular

Bridging the Gender Gap: Addressing Women’s Underrepresentation in Cardiovascular Research, American Journal of Managed Care, October 15, 2024 Read Post »

The Rise of the “Expert” Patient: Opportunities and Challenges in Democratizing Drug Development

For many years, drug development has lagged behind healthcare in engaging patients. Recently, however, the field has shifted toward more active patient involvement, recognizing the value of patient insights both for democratizing drug creation and enhancing innovation. A recent article published in “Science is Culture” analyzes the potential and challenges of involving patients in drug

The Rise of the “Expert” Patient: Opportunities and Challenges in Democratizing Drug Development Read Post »

TRANSLATE »
Scroll to Top